B7-33 2mg 10vials

Description

B7-33 Relaxin RXFP1 Agonist for Fibrosis & Tissue Research

Mechanism Overview

The biochemical activity of B7-33 is defined by its high-affinity interaction with the extracellular loops of the RXFP1 receptor. The primary mechanism involves the peptide binds to the receptor, initiating a conformational shift that recruits G-proteins and stimulates the pERK1/2 signaling cascade. This defines the first semantic triple: [B7-33 activates RXFP1]. Following this, this intracellular signaling induces the expression of Matrix Metalloproteinases (MMPs), particularly MMP-2 and MMP-9. This establishes the second triple: [RXFP1 activation promotes MMP expression]. Thirdly, these enzymes selectively degrade excessive extracellular matrix components, such as collagen type I and III, while simultaneously inhibiting the pro-fibrotic effects of Transforming Growth Factor-beta 1 (TGF-beta1). This forms the third triple: [B7-33 inhibits collagen accumulation]. Quantitatively, B7-33 demonstrates a pEC50 of approximately 8.4 at the RXFP1 receptor in functional assays. Unlike native H2 relaxin, which is a complex two-chain disulfide-linked hormone, B7-33 is a single-chain decapeptide that offers superior research feasibility due to its simplified structure and reduced pleiotropic signaling.

Molecular Data

• CAS Number: 1204646-60-7
• Molecular Formula: C130H214N38O34
• Molecular Weight: 2913.4 Da
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Experimental Outcomes

• Systemic Anti-Fibrotic Activity: Users report significant improvements in biomarkers of tissue scarring in pulmonary, cardiac, and renal research models.
• Enhanced Vascular Compliance: Published research indicates a marked reduction in systemic vascular resistance and improved blood flow through relaxin-mediated vasodilation.
• Collagen Remodeling: According to research documentation, research models show accelerated turnover of pathological collagen deposition in chronic injury settings.
• Renal Protective Signaling: Cumulative findings indicate improved glomerular filtration rates and reduced tubular fibrosis in models of chronic kidney stress.
• Cardiac Remodeling Support: Research models have observed a reduction in left ventricular stiffness and improved diastolic function following administration.

Compound Background

B7-33 is a synthetic, single-chain peptide analog derived from the human gene-2 (H2) relaxin, specifically engineered to act as a potent agonist of the relaxin family peptide receptor 1 (RXFP1). This signaling molecule serves as a critical research tool for investigating the reversal of pathological fibrosis and the modulation of vascular resistance. Unlike the full-length relaxin hormone, B7-33 is functionally biased toward pERK1/2 signaling pathways over cAMP accumulation in specific tissue types.
Key Points:
B7-33 represents a high-feasibility research tool for investigating the targeted reversal of fibrosis and the molecular mechanisms of RXFP1 signaling.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.